Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertisers
    • Advertise
    • PR Submissions
    • Eblast Submissions
  • SUBSCRIBE

Astellas to spend $70M on new biotech campus in South San Francisco

By Brian Buntz | July 29, 2022

AstellasAstellas Pharma (TSE: 4503) plans to establish a biotech campus in South San Francisco, California, as the core of its West Coast R&D operations.

Located near Genentech and Verily Life Sciences facilities, the site at 480 Forbes Boulevard will consolidate several Astellas business units and functions currently based throughout the San Francisco Bay Area.

The operations will be housed in a 154,000-ft2 building.

The company plans to spend $70 million to construct the new facility, including lab and co-working space.

Astellas has ramped up its focus on cell and gene therapy following its 2019 acquisition of Audentes Therapeutics for approximately $3 billion. Astellas Pharma is among the largest cell and gene therapy firms in the world.

Astellas already has an East Coast biomedical innovation hub in Boston area.

The company anticipates completing the construction of the new site in the summer of 2023.

About The Author

Brian Buntz

The pharma and biotech editor of WTWH Media, Brian is a veteran journalist with more than 15 years of experience covering an array of life science topics, including clinical trials, drug discovery and development and medical devices. Before coming to WTWH, he served as content director focused on connected devices at Informa. In addition, Brian covered the medical device sector for 10 years at UBM. At Qmed, he overhauled the brand’s news coverage and helped to grow the site’s traffic volume dramatically. He had previously held managing editor roles on two of the company’s medical device technology publications. Connect with him on LinkedIn or email at [email protected].

Tell Us What You Think! Cancel reply

Related Articles Read More >

GSK
GSK invests another $800M in Pennsylvania site expansions
This is a BD image of its major IV catheters manufacturing facility in Sandy, Utah, which the company said produces billions of molded components each year.
BD to invest billions in U.S. manufacturing
Diverse factory workers in yellow PPE suits checking production data with clipboard in modern industrial facility, Quality control inspector wearing masks and hairnets working in food or pharma plant
ISO 9001, 14001 and 45001 revisions: What changes and when to start
Artis BioSolutions announces new center of excellence in Spain
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2026 Arrowfly LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Arrowfly
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertisers
    • Advertise
    • PR Submissions
    • Eblast Submissions
  • SUBSCRIBE